Key facts
- This page summarizes Helix Holdings LLC's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Apr 2022, 18:28.
Helix Holdings LLC - 05 Apr 2022 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)
- Reporting relationship
- Former 10% Holder
- Issuer ticker
- MLTX
- Reported as of
- 05 Apr 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Bihua Chen, Managing Member
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Helix Holdings LLC filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 07 Apr 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MLTX
transaction
Class A Ordinary Shares
Conversion of derivative security
- Transaction value
- $0
- Shares
- +2,785,000
- Change %
- +648%
- Price
- $0.000000
- Shares after
- 3,215,000
- Date
- 05 Apr 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MLTX
transaction
Derivative
Class B Ordinary Shares
Conversion of derivative security
- Transaction value
- Shares
- -2,785,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 05 Apr 2022
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 2,785,000
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Helix Holdings LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Each of the Issuer's Class B Ordinary Shares were convertible into Class A Ordinary Shares upon consummation of the Issuer's initial business combination and had no expiration date. In connection with the consummation of the Issuer's initial business combination ("Business Combination") and pursuant to the Business Combination Agreement dated as of October 4, 2021, by and between the Issuer, MoonLake Immunotherapeutics AG, and the other parties thereto (the "Business Combination Agreement"), such Class B Ordinary Shares automatically converted into an equal number of Class A Ordinary Shares.
Footnote F2
Helix Holdings LLC is the record holder of these securities reported. Bihua Chen is the manager of Helix Holdings LLC and has voting and investment discretion with respect to the securities held of record by Helix Holdings LLC. Ms. Chen disclaims any beneficial ownership of the securities held by Helix Holdings LLC other than to the extent of any pecuniary interest she may have therein, directly or indirectly.